Literature DB >> 30255316

Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial.

Jennifer M Kaplan1, Basilia Zingarelli2, Kelli Krallman2, Sonya Tang Girdwood2, Denise Lagory3, Tomoyuki Mizuno4, Lin Fei5, Hector R Wong2, Alexander A Vinks4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30255316      PMCID： PMC6235707          DOI： 10.1007/s00134-018-5374-7

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

1.  Health-related outcomes of critically ill patients with and without sepsis.

Authors:  Kelly Thompson; Colman Taylor; Stephen Jan; Qiang Li; Naomi Hammond; John Myburgh; Manoj Saxena; Balasubramanian Venkatesh; Simon Finfer
Journal:  Intensive Care Med       Date:  2018-06-27       Impact factor: 17.440

2.  Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes.

Authors:  Michael L Christensen; Bernd Meibohm; Edmund V Capparelli; Pedro Velasquez-Mieyer; George A Burghen; William V Tamborlane
Journal:  J Clin Pharmacol       Date:  2005-10       Impact factor: 3.126

3.  Prediction of pediatric sepsis mortality within 1 h of intensive care admission.

Authors:  Luregn J Schlapbach; Graeme MacLaren; Marino Festa; Janet Alexander; Simon Erickson; John Beca; Anthony Slater; Andreas Schibler; David Pilcher; Johnny Millar; Lahn Straney
Journal:  Intensive Care Med       Date:  2017-02-20       Impact factor: 17.440

4.  15-Deoxy-delta(12,14)-prostaglandin J(2) (15D-PGJ(2)), a peroxisome proliferator activated receptor gamma ligand, reduces tissue leukosequestration and mortality in endotoxic shock.

Authors:  Jennifer M Kaplan; James A Cook; Paul W Hake; Michael O'Connor; Timothy J Burroughs; Basilia Zingarelli
Journal:  Shock       Date:  2005-07       Impact factor: 3.454

5.  Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock.

Authors:  Jennifer M Kaplan; Alvin Denenberg; Marie Monaco; Marchele Nowell; Hector Wong; Basilia Zingarelli
Journal:  Intensive Care Med       Date:  2009-09-17       Impact factor: 17.440
  5 in total
  3 in total

Review 1.  Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.

Authors:  Hong Sheng Cheng; Wei Ren Tan; Zun Siong Low; Charlie Marvalim; Justin Yin Hao Lee; Nguan Soon Tan
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

Review 2.  Anti-Hyperglycemic Agents in the Adjuvant Treatment of Sepsis: Improving Intestinal Barrier Function.

Authors:  Yi-Feng Wang; Jia-Wei Li; Da-Peng Wang; Ke Jin; Jiao-Jie Hui; Hong-Yang Xu
Journal:  Drug Des Devel Ther       Date:  2022-06-04       Impact factor: 4.319

3.  Type 2 Diabetic Sepsis Patients Have a Lower Mortality Rate in Pioglitazone Use: A Nationwide 15-Year Propensity Score Matching Observational Study in Taiwan.

Authors:  Ming-Shun Hsieh; Sung-Yuan Hu; Shu-Hui Liao; Chia-Ming Chang; Vivian Chia-Rong Hsieh; Chorng-Kuang How
Journal:  Emerg Med Int       Date:  2021-07-23       Impact factor: 1.112
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.